世界の慢性骨髄性白血病治療市場インサイト及び予測(~2026年)

【英語タイトル】Global Chronic Myelogenous Leukemia Treatment Market Size, Status and Forecast 2020-2026

QYResearchが出版した調査資料(QYR20NV11370)・商品コード:QYR20NV11370
・発行会社(調査会社):QYResearch
・発行日:2020年11月
・ページ数:96
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥421,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥631,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥842,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートは慢性骨髄性白血病治療の世界市場について調査・分析した資料です。種類別(疾患特異的治療、対症療法)の市場規模、用途別(病院薬局、専門薬局、小売薬局)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別慢性骨髄性白血病治療の競争状況、市場シェア
・世界の慢性骨髄性白血病治療市場:種類別市場規模 2015年-2020年(疾患特異的治療、対症療法)
・世界の慢性骨髄性白血病治療市場:種類別市場規模予測 2021年-2026年(疾患特異的治療、対症療法)
・世界の慢性骨髄性白血病治療市場:用途別市場規模 2015年-2020年(病院薬局、専門薬局、小売薬局)
・世界の慢性骨髄性白血病治療市場:用途別市場規模予測 2021年-2026年(病院薬局、専門薬局、小売薬局)
・北米の慢性骨髄性白血病治療市場分析:米国、カナダ
・ヨーロッパの慢性骨髄性白血病治療市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの慢性骨髄性白血病治療市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の慢性骨髄性白血病治療市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの慢性骨髄性白血病治療市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Bristol-Myers Squibb、Novartis、Pfizer、Teva Pharmaceuticals、Roche、Incyte、Bio-Path Holdings
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. It’s a type of cancer that starts in certain blood-forming cells of the bone marrow.

Market Analysis and Insights: Global Chronic Myelogenous Leukemia Treatment Market
The global Chronic Myelogenous Leukemia Treatment market size is projected to reach US$ 4636.8 million by 2026, from US$ 4453.9 million in 2020, at a CAGR of 3.8%% during 2021-2026.

Global Chronic Myelogenous Leukemia Treatment Scope and Market Size
Chronic Myelogenous Leukemia Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chronic Myelogenous Leukemia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Bristol-Myers Squibb
Novartis
Pfizer
Teva Pharmaceuticals
Roche
Incyte
Bio-Path Holdings

Market segment by Type, the product can be split into
Disease Specific Treatment
Symptomatic Treatment
Market segment by Application, split into
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Chronic Myelogenous Leukemia Treatment Revenue
1.4 Market by Type
1.4.1 Global Chronic Myelogenous Leukemia Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Disease Specific Treatment
1.4.3 Symptomatic Treatment
1.5 Market by Application
1.5.1 Global Chronic Myelogenous Leukemia Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Specialty Pharmacies
1.5.4 Retail Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Chronic Myelogenous Leukemia Treatment Market Perspective (2015-2026)
2.2 Global Chronic Myelogenous Leukemia Treatment Growth Trends by Regions
2.2.1 Chronic Myelogenous Leukemia Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Chronic Myelogenous Leukemia Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Chronic Myelogenous Leukemia Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Chronic Myelogenous Leukemia Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Chronic Myelogenous Leukemia Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Chronic Myelogenous Leukemia Treatment Players by Market Size
3.1.1 Global Top Chronic Myelogenous Leukemia Treatment Players by Revenue (2015-2020)
3.1.2 Global Chronic Myelogenous Leukemia Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Chronic Myelogenous Leukemia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Chronic Myelogenous Leukemia Treatment Market Concentration Ratio
3.2.1 Global Chronic Myelogenous Leukemia Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Chronic Myelogenous Leukemia Treatment Revenue in 2019
3.3 Chronic Myelogenous Leukemia Treatment Key Players Head office and Area Served
3.4 Key Players Chronic Myelogenous Leukemia Treatment Product Solution and Service
3.5 Date of Enter into Chronic Myelogenous Leukemia Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Chronic Myelogenous Leukemia Treatment Historic Market Size by Type (2015-2020)
4.2 Global Chronic Myelogenous Leukemia Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020)
5.2 Global Chronic Myelogenous Leukemia Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Chronic Myelogenous Leukemia Treatment Market Size (2015-2020)
6.2 Chronic Myelogenous Leukemia Treatment Key Players in North America (2019-2020)
6.3 North America Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020)
6.4 North America Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Chronic Myelogenous Leukemia Treatment Market Size (2015-2020)
7.2 Chronic Myelogenous Leukemia Treatment Key Players in Europe (2019-2020)
7.3 Europe Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020)
7.4 Europe Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020)

8 China
8.1 China Chronic Myelogenous Leukemia Treatment Market Size (2015-2020)
8.2 Chronic Myelogenous Leukemia Treatment Key Players in China (2019-2020)
8.3 China Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020)
8.4 China Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Chronic Myelogenous Leukemia Treatment Market Size (2015-2020)
9.2 Chronic Myelogenous Leukemia Treatment Key Players in Japan (2019-2020)
9.3 Japan Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020)
9.4 Japan Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Chronic Myelogenous Leukemia Treatment Market Size (2015-2020)
10.2 Chronic Myelogenous Leukemia Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020)

11 India
11.1 India Chronic Myelogenous Leukemia Treatment Market Size (2015-2020)
11.2 Chronic Myelogenous Leukemia Treatment Key Players in India (2019-2020)
11.3 India Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020)
11.4 India Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Chronic Myelogenous Leukemia Treatment Market Size (2015-2020)
12.2 Chronic Myelogenous Leukemia Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020)
12.4 Central & South America Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Bristol-Myers Squibb
13.1.1 Bristol-Myers Squibb Company Details
13.1.2 Bristol-Myers Squibb Business Overview
13.1.3 Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Introduction
13.1.4 Bristol-Myers Squibb Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020))
13.1.5 Bristol-Myers Squibb Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Chronic Myelogenous Leukemia Treatment Introduction
13.2.4 Novartis Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview
13.3.3 Pfizer Chronic Myelogenous Leukemia Treatment Introduction
13.3.4 Pfizer Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Teva Pharmaceuticals
13.4.1 Teva Pharmaceuticals Company Details
13.4.2 Teva Pharmaceuticals Business Overview
13.4.3 Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Introduction
13.4.4 Teva Pharmaceuticals Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020)
13.4.5 Teva Pharmaceuticals Recent Development
13.5 Roche
13.5.1 Roche Company Details
13.5.2 Roche Business Overview
13.5.3 Roche Chronic Myelogenous Leukemia Treatment Introduction
13.5.4 Roche Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020)
13.5.5 Roche Recent Development
13.6 Incyte
13.6.1 Incyte Company Details
13.6.2 Incyte Business Overview
13.6.3 Incyte Chronic Myelogenous Leukemia Treatment Introduction
13.6.4 Incyte Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020)
13.6.5 Incyte Recent Development
13.7 Bio-Path Holdings
13.7.1 Bio-Path Holdings Company Details
13.7.2 Bio-Path Holdings Business Overview
13.7.3 Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Introduction
13.7.4 Bio-Path Holdings Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020)
13.7.5 Bio-Path Holdings Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Chronic Myelogenous Leukemia Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Chronic Myelogenous Leukemia Treatment Revenue
Table 3. Ranking of Global Top Chronic Myelogenous Leukemia Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Chronic Myelogenous Leukemia Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Disease Specific Treatment
Table 6. Key Players of Symptomatic Treatment
Table 7. Global Chronic Myelogenous Leukemia Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Chronic Myelogenous Leukemia Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Chronic Myelogenous Leukemia Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Chronic Myelogenous Leukemia Treatment Market Share by Regions (2015-2020)
Table 11. Global Chronic Myelogenous Leukemia Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Chronic Myelogenous Leukemia Treatment Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Chronic Myelogenous Leukemia Treatment Market Growth Strategy
Table 17. Main Points Interviewed from Key Chronic Myelogenous Leukemia Treatment Players
Table 18. Global Chronic Myelogenous Leukemia Treatment Revenue by Players (2015-2020) (Million US$)
Table 19. Global Chronic Myelogenous Leukemia Treatment Market Share by Players (2015-2020)
Table 20. Global Top Chronic Myelogenous Leukemia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Myelogenous Leukemia Treatment as of 2019)
Table 21. Global Chronic Myelogenous Leukemia Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Chronic Myelogenous Leukemia Treatment Product Solution and Service
Table 24. Date of Enter into Chronic Myelogenous Leukemia Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020) (Million US$)
Table 27. Global Chronic Myelogenous Leukemia Treatment Market Size Share by Type (2015-2020)
Table 28. Global Chronic Myelogenous Leukemia Treatment Revenue Market Share by Type (2021-2026)
Table 29. Global Chronic Myelogenous Leukemia Treatment Market Size Share by Application (2015-2020)
Table 30. Global Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020) (Million US$)
Table 31. Global Chronic Myelogenous Leukemia Treatment Market Size Share by Application (2021-2026)
Table 32. North America Key Players Chronic Myelogenous Leukemia Treatment Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Chronic Myelogenous Leukemia Treatment Market Share (2019-2020)
Table 34. North America Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020) (Million US$)
Table 35. North America Chronic Myelogenous Leukemia Treatment Market Share by Type (2015-2020)
Table 36. North America Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020) (Million US$)
Table 37. North America Chronic Myelogenous Leukemia Treatment Market Share by Application (2015-2020)
Table 38. Europe Key Players Chronic Myelogenous Leukemia Treatment Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Chronic Myelogenous Leukemia Treatment Market Share (2019-2020)
Table 40. Europe Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Chronic Myelogenous Leukemia Treatment Market Share by Type (2015-2020)
Table 42. Europe Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Chronic Myelogenous Leukemia Treatment Market Share by Application (2015-2020)
Table 44. China Key Players Chronic Myelogenous Leukemia Treatment Revenue (2019-2020) (Million US$)
Table 45. China Key Players Chronic Myelogenous Leukemia Treatment Market Share (2019-2020)
Table 46. China Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020) (Million US$)
Table 47. China Chronic Myelogenous Leukemia Treatment Market Share by Type (2015-2020)
Table 48. China Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020) (Million US$)
Table 49. China Chronic Myelogenous Leukemia Treatment Market Share by Application (2015-2020)
Table 50. Japan Key Players Chronic Myelogenous Leukemia Treatment Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Chronic Myelogenous Leukemia Treatment Market Share (2019-2020)
Table 52. Japan Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Chronic Myelogenous Leukemia Treatment Market Share by Type (2015-2020)
Table 54. Japan Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Chronic Myelogenous Leukemia Treatment Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Chronic Myelogenous Leukemia Treatment Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Chronic Myelogenous Leukemia Treatment Market Share (2019-2020)
Table 58. Southeast Asia Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Chronic Myelogenous Leukemia Treatment Market Share by Type (2015-2020)
Table 60. Southeast Asia Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Chronic Myelogenous Leukemia Treatment Market Share by Application (2015-2020)
Table 62. India Key Players Chronic Myelogenous Leukemia Treatment Revenue (2019-2020) (Million US$)
Table 63. India Key Players Chronic Myelogenous Leukemia Treatment Market Share (2019-2020)
Table 64. India Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020) (Million US$)
Table 65. India Chronic Myelogenous Leukemia Treatment Market Share by Type (2015-2020)
Table 66. India Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020) (Million US$)
Table 67. India Chronic Myelogenous Leukemia Treatment Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Chronic Myelogenous Leukemia Treatment Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Chronic Myelogenous Leukemia Treatment Market Share (2019-2020)
Table 70. Central & South America Chronic Myelogenous Leukemia Treatment Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Chronic Myelogenous Leukemia Treatment Market Share by Type (2015-2020)
Table 72. Central & South America Chronic Myelogenous Leukemia Treatment Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Chronic Myelogenous Leukemia Treatment Market Share by Application (2015-2020)
Table 74. Bristol-Myers Squibb Company Details
Table 75. Bristol-Myers Squibb Business Overview
Table 76. Bristol-Myers Squibb Product
Table 77. Bristol-Myers Squibb Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020) (Million US$)
Table 78. Bristol-Myers Squibb Recent Development
Table 79. Novartis Company Details
Table 80. Novartis Business Overview
Table 81. Novartis Product
Table 82. Novartis Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020) (Million US$)
Table 83. Novartis Recent Development
Table 84. Pfizer Company Details
Table 85. Pfizer Business Overview
Table 86. Pfizer Product
Table 87. Pfizer Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020) (Million US$)
Table 88. Pfizer Recent Development
Table 89. Teva Pharmaceuticals Company Details
Table 90. Teva Pharmaceuticals Business Overview
Table 91. Teva Pharmaceuticals Product
Table 92. Teva Pharmaceuticals Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020) (Million US$)
Table 93. Teva Pharmaceuticals Recent Development
Table 94. Roche Company Details
Table 95. Roche Business Overview
Table 96. Roche Product
Table 97. Roche Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020) (Million US$)
Table 98. Roche Recent Development
Table 99. Incyte Company Details
Table 100. Incyte Business Overview
Table 101. Incyte Product
Table 102. Incyte Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020) (Million US$)
Table 103. Incyte Recent Development
Table 104. Bio-Path Holdings Company Details
Table 105. Bio-Path Holdings Business Overview
Table 106. Bio-Path Holdings Product
Table 107. Bio-Path Holdings Revenue in Chronic Myelogenous Leukemia Treatment Business (2015-2020) (Million US$)
Table 108. Bio-Path Holdings Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Myelogenous Leukemia Treatment Market Share by Type: 2020 VS 2026
Figure 2. Disease Specific Treatment Features
Figure 3. Symptomatic Treatment Features
Figure 4. Global Chronic Myelogenous Leukemia Treatment Market Share by Application: 2020 VS 2026
Figure 5. Hospital Pharmacies Case Studies
Figure 6. Specialty Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. Chronic Myelogenous Leukemia Treatment Report Years Considered
Figure 9. Global Chronic Myelogenous Leukemia Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Chronic Myelogenous Leukemia Treatment Market Share by Regions: 2020 VS 2026
Figure 11. Global Chronic Myelogenous Leukemia Treatment Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Chronic Myelogenous Leukemia Treatment Market Share by Players in 2019
Figure 14. Global Top Chronic Myelogenous Leukemia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Myelogenous Leukemia Treatment as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Chronic Myelogenous Leukemia Treatment Revenue in 2019
Figure 16. North America Chronic Myelogenous Leukemia Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Chronic Myelogenous Leukemia Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Chronic Myelogenous Leukemia Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Chronic Myelogenous Leukemia Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Chronic Myelogenous Leukemia Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Chronic Myelogenous Leukemia Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Chronic Myelogenous Leukemia Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed


【掲載企業】

Bristol-Myers Squibb、Novartis、Pfizer、Teva Pharmaceuticals、Roche、Incyte、Bio-Path Holdings

★調査レポート[世界の慢性骨髄性白血病治療市場インサイト及び予測(~2026年)] (コード:QYR20NV11370)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の慢性骨髄性白血病治療市場インサイト及び予測(~2026年)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆